Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 549Carcinoma, Non-Small-Cell Lung 509Prostatic Neoplasms 333Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 262Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 214Lung Neoplasms 207Neoplasm Metastasis 203Carcinoma, Hepatocellular 197Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 133Glioblastoma 132Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 125Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

spartalizumab 1pembrolizumab 1Radiosurgery 1Oncolytic Virotherapy 1Leucovorin 1Irinotecan 1IFL protocol 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × CRC × 1 year × Clear all
NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡